Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections

Sonia Luque, Carol Escaño, Luisa Sorli, Jian Li, Nuria Campillo, Juan Pablo Horcajada, Esther Salas, Santiago Grau
Sonia Luque
aPharmacy Department, Hospital del Mar, Barcelona, Spain
bInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Escaño
dInfectious Diseases Department, Hospital del Mar, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa Sorli
bInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
dInfectious Diseases Department, Hospital del Mar, Barcelona, Spain
fUniversitat Pompeu Fabra, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Li
eMonash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuria Campillo
aPharmacy Department, Hospital del Mar, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Pablo Horcajada
bInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
dInfectious Diseases Department, Hospital del Mar, Barcelona, Spain
fUniversitat Pompeu Fabra, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Salas
aPharmacy Department, Hospital del Mar, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santiago Grau
aPharmacy Department, Hospital del Mar, Barcelona, Spain
bInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
cUniversitat Autónoma de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02595-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Limited information is available on the urinary excretion of colistin in infected patients. This study aimed to investigate the pharmacokinetics of colistimethate sodium (CMS) and formed colistin in urine in patients with multidrug-resistant (MDR) Gram-negative bacterial infections. A pharmacokinetic study was conducted on 12 patients diagnosed with an infection caused by an extremely drug-resistant (XDR) P. aeruginosa strain and treated with intravenous CMS. Fresh urine samples were collected at 2-h intervals, and blood samples were collected predose (Cmin ss) and at the end of the CMS infusion (Cmax ss) for measurement of concentrations of CMS and formed colistin using high-performance liquid chromatography (HPLC). CMS urinary recovery was determined as the summed amount of CMS and formed colistin recovered in urine for each 2-h interval divided by the CMS dose. There were 12 enrolled patients, 9 of whom were male (75%). Data [median (range)] were as follows: age, 65.5 (37 to 86) years; colistimethate urinary recovery 0 to 6 h, 42.6% (2.9% to 72.8%); range of concentrations of colistin in urine, <0.1 to 95.4 mg/liter; Cmin ss and Cmax ss of colistin in plasma, 0.9 (<0.2 to 1.4) and 0.9 (<0.2 to 1.4) mg/liter, respectively. In 6/12 (50%) patients, more than 40% of the CMS dose was recovered in the urine within the first 6 h after CMS administration. This study demonstrated rapid urinary excretion of CMS in patients within the first 6 h after intravenous administration. In all but one patient, the concentrations of formed colistin in urine were above the MIC for the most predominant isolate of P. aeruginosa in our hospital. Future studies are warranted for optimizing CMS dosage regimens in urinary tract infection (UTI) patients.

INTRODUCTION

Colistin has emerged as a last-line therapy in the last decade for the treatment of nosocomial infections caused by multidrug-resistant (MDR) Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii (1). Despite several recent clinical studies evaluating the pharmacokinetics of colistin and its prodrug colistimethate sodium (CMS) in plasma in different types of patients (2–13), very limited information is available on the recovery of CMS and formed colistin in urine from patients. Only three studies have evaluated urinary excretion and concentrations in urine in healthy volunteers (14–16), two in cystic fibrosis patients (3, 6) and two studies on patients undergoing renal replacement therapies (RRT) (4, 5). A better understanding of the urinary recovery of CMS and formed colistin is important for investigation of colistin-associated nephrotoxicity, the major dose-limiting factor, and optimizing intravenous CMS doses for treatment of urinary tract infections (UTI) caused by MDR Gram-negative pathogens. The present study aimed to examine the pharmacokinetics of CMS and formed colistin in urine in patients with MDR Gram-negative bacterial infections and the relationship between urinary concentrations of CMS and formed colistin and colistin-associated nephrotoxicity.

RESULTS

During the study period, 12 patients were enrolled, including 9 males (75%), with a median (range) age of 65.5 (37 to 86) years. All of them presented with an MDR Gram-negative bacterial infection caused by an MDR P. aeruginosa strain: 5 (41.7%) respiratory tract, 4 (33.3%) urinary tract, 2 (16.7%) intra-abdominal, and 1 (8.3%) skin and soft tissue infection. The median (range) CMS treatment duration and length of hospital stay were 15 (8 to 34) and 26.5 (14 to 102) days, respectively, and none of the patients died.

The characteristics of the patients and concentrations of CMS and formed colistin in plasma and urine are presented in Tables 1 and 2.

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics of the included patients and plasma CMS and formed colistin concentrations

View this table:
  • View inline
  • View popup
TABLE 2

Urine recovery of CMS and formed colistin

Two of the four patients diagnosed with a UTI caused by an MDR P. aeruginosa strain achieved clinical cure (patients 3 and 9), and the other two patients could not be evaluated (one due to the presence of Enterococcus faecalis in the urine [patient 1] and the other with orchyepidemitis due to the same strain of MDR P. aeruginosa [patient 12]). Three of these four patients (75%) achieved microbiological eradication (patients 3, 9, and 12), while for the third (patient 1), no further cultures were performed.

For two of the three patients (3 and 9) with UTI who achieved microbiological cure, the CMS urinary recovery rates were 47.6% and 72.8% (Table 2). For the third (patient 12), the CMS concentrations could not be determined due to technical issues. For the patient with persistence of positive urinary cultures, the CMS urinary recovery was much lower (2.9%) (patient 1) (Table 2). This patient had severe renal impairment at the beginning of the CMS treatment.

In all the patients, the concentration of formed colistin in plasma was below the suggested therapeutic level of 2.5 mg/liter (8). In all but one patient, the concentration of colistin in urine was much higher than those achieved in plasma and also above the MIC (0.5 mg/liter) for the most predominant strain of P. aeruginosa in our hospital.

The maximum concentration of CMS achieved in urine per dose was not correlated with the initial estimated glomerular filtration rate (eGFR) (Spearman rho, 0.436; P = 0.180) or the initial serum creatinine level (Spearman rho, −0.364; P = 0.272). In 6/12 (50%) patients, more than 40% of the CMS dose was recovered in the urine within the first 6 h after CMS administration. The daily CMS dose (in milligrams) showed a significantly positive linear correlation with the maximum concentrations of CMS observed in urine during the first 6 h (rho, 0.837; P = 0.001) and also with the CMS urinary recovery within 6 h (rho, 0.608; P = 0.047).

At the end of the treatment, nephrotoxicity was present in only 3 (25%) of the patients (1 with risk stage[R] and 2 with injury stage [I] according to RIFLE categories), who also received other nephrotoxicity drugs (Table 2). The CMS urinary recovery rates were not different between patients with and without nephrotoxicity at the end of treatment (25.3% [range, 20.9% to 49.0%] and 45.1% [2.9% to 72.8%; P > 0.999], respectively). In addition, the CMS urinary recovery was not correlated with the final serum creatinine level or final eGFR (Spearman rho, −0.373, P = 0.259, and Spearman rho, 0.436, P = 0.180, respectively).

DISCUSSION

Colistin use has reemerged in recent years for the treatment of MDR Gram-negative bacterial infections. However, limited information is available on its pharmacokinetics in urine in infected patients. Our present study is the first pharmacokinetic study of CMS and formed colistin in urine in patients with MDR Gram-negative bacterial infections who are not undergoing any RRT and with urine samples collected at 2-h intervals over 6 h. The 2 more recent studies that examined the urinary excretion of CMS and formed colistin in healthy volunteers showed high urinary excretion of CMS (13, 14). In the most recent study by Couet et al., the urinary excretion of CMS was reported to be 70% after the administration of a single dose of 1 million IU (MIU) of CMS. This fact could be explained by the high estimated typical renal clearance of CMS (103 ml/min), a value close to the glomerular filtration rate. In our present study, the urinary excretion of CMS within the first 6 h after CMS administration was >40% in half of the patients. Although the majority of our patients had poor initial renal function (for 4 of them, the initial eGFR was <60 ml/min), no correlation was observed between the initial renal function (eGFR) and the urinary concentration of CMS.

CMS is mainly eliminated by the kidneys, with extensive secretion after filtration by glomeruli in the kidney, while the positively charged colistin undergoes substantial reabsorption by the renal tubular cells (1). Our results showed high excretion of the CMS dose in the first 6 h after administration (more than 40% of the administered CMS dose in 50% of the 12 patients) (Table 1). Compared to the two studies of healthy volunteers, urine samples in our study were collected fresh, immediately transported on ice, centrifuged in a cold room, and frozen at −80°C; this procedure minimized any potential postexcretion hydrolysis of CMS. Almost all of the 12 patients in this study achieved high urinary concentrations of colistin (0.5 to 95.4 mg/liter), the antibacterial entity formed from CMS, and the concentrations were equal to or above the MIC value (0.5 mg/liter) for the most predominant isolate of P. aeruginosa in our hospital. The exposure of formed colistin in plasma in our patients was much lower than in the urine within 6 h. This was due to the fact that only a very small fraction of the CMS dose that was not excreted in urine was converted to colistin in blood (1). Our study has a small sample size, and large clinical pharmacokinetic/pharmacodynamic studies are warranted to evaluate whether doses of CMS lower than the current recommendation should be administered for the treatment of UTI to reduce the high incidence of colistin-associated nephrotoxicity. A linear correlation was observed between the CMS dose and the CMS urinary concentrations, and it is very likely that lower doses of CMS could lead to lower concentrations of CMS in urine. However, no studies have evaluated the potential impact of the plasma or urine CMS concentration or the colistin levels in urine and the appearance of nephrotoxicity.

In our study, nephrotoxicity at the end of treatment was observed in 3 (25%) patients, with one at stage R (risk) and two at stage I (injury). These three patients presented CMS urinary recovery rates of 25.3% (R; patient 2), 20.9% (I; patient 6), and 49.0% (I; patient 8), and the Cmax ss and Cmin ss of formed colistin in plasma were lower than the cutoff point predictor of nephrotoxicity proposed by our group (2.42 mg/liter) (7). Consequently, this adverse event did not seem to be related to a high exposure to colistin or CMS in plasma.

The urinary formed colistin concentrations were high (4.5 to 15.8 mg/liter in patient 6 and 8.5 to 21.3 mg/liter in patient 8) in two patients but very low in the third (0.1 to 0.6 mg/liter in patient 2). In addition, all 3 patients were receiving at least other nephrotoxic drugs, such as furosemide, amikacin, or vancomycin nonsteroidal anti-inflammatory drugs (NSAIDs). Consequently, the presence of these concomitant nephrotoxic drugs could also have influenced the occurrence of nephrotoxicity. In addition, CMS urinary recovery rates were not different between patients with and without nephrotoxicity at the end of treatment, and they showed a correlation only with the CMS initial dose. For all these reasons, the real influence of CMS and colistin levels in urine on the incidence of nephrotoxicity should be evaluated in a larger clinical study.

In conclusion, our study demonstrated rapid urinary excretion of CMS within the first 6 h in patients after intravenous administration. Larger clinical studies are warranted in future for optimizing CMS dosage regimens in UTI patients in order to optimize its use in this specific patient population while minimizing any potential nephrotoxicity.

MATERIALS AND METHODS

Patients.This was a prospective pharmacokinetic study conducted with 12 patients with MDR Gram-negative bacterial infections treated with intravenous CMS in a university hospital from January to September 2014. All the patients were diagnosed with infection caused by an extremely drug-resistant (XDR) P. aeruginosa strain and treated with intravenous CMS for at least 48 h. Exclusion criteria were an age of <18 years, pregnancy or breastfeeding, and the need for renal replacement therapies. Informed consent was obtained from all participating patients or their legal representatives. The study protocol was approved by the Clinical Research Ethical Committees (CEIC), Parc de Salut Mar.

Data collection.The following clinical data were collected: demographics, type of MDR Gram-negative bacterial infection, CMS daily dose (selected by the responsible clinician), number of days of treatment, renal function at the start and end of CMS therapy (serum creatinine and eGFR by the Modification of Diet in Renal Disease [4-variable version] [MDRD-4] equation), presence of nephrotoxicity at the end of treatment evaluated by the RIFLE criteria (17), other concomitantly administered nephrotoxic drugs (e.g., NSAIDs, furosemide, contrast agent, angiotensin-converting enzyme inhibitors, aminoglycosides, and vancomycin), and crude mortality during hospital admission. CMS for injection (GES Genéricos Españoles) was dosed in MIU (range, 1 to 9 MIU/day). The prescribed dose of CMS was administered intravenously in 100 ml normal saline over 30 min with the commercially available CMS formulation for injection, each vial containing 1 MIU of CMS (equivalent to 30 mg colistin base activity [CBA] or 80 mg CMS) (19).

Pharmacokinetic study.Three-milliliter blood samples were collected immediately predose (Cmin ss) and 30 minutes after the end of infusion (Cmax ss) on day 3 or 4 of treatment (when steady state was achieved).

Fresh directly voided urine samples were collected from 0 to 2 h, 2 to 4 h, and 4 to 6 h after the start of the CMS infusion. The CMS/colistin concentration was calculated at that time and then multiplied by the volume of urine to obtain the total amount of CMS excreted renally over the time frame. Concentrations of CMS and formed colistin in plasma and urine samples were measured by validated high-performance liquid chromatography (HPLC) methods (20, 21), with minor modifications as described previously (7). The urinary recovery of CMS was determined as the summed amount of CMS and formed colistin (after conversion using different molecular weights) recovered in urine during the collection period divided by the dose of CMS (18). Nephrotoxicity during CMS treatment was defined as a 1.5-fold or more increase in serum creatinine and/or a decrease in the eGFR of >25 (17).

Statistical analysis.Quantitative variables were expressed as median and interquartile range, and a Spearman test was employed for bivariate correlations. The Statistical Package for the Social Sciences (SPSS) version 15.0 was employed. For all analyses, a two-sided P value of <0.05 was considered to be statistically significant.

FOOTNOTES

    • Received 7 December 2016.
    • Returned for modification 27 January 2017.
    • Accepted 13 May 2017.
    • Accepted manuscript posted online 30 May 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Li J,
    2. Nation RL,
    3. Turnidge JD,
    4. Milne RW,
    5. Coulthard K,
    6. Rayner CR,
    7. Paterson DL
    . 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis6:589. doi:10.1016/S1473-3099(06)70580-1.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Grégoire N,
    2. Mimoz O,
    3. Mégarbane B,
    4. Comets E,
    5. Chatelier D,
    6. Lasocki S,
    7. Gauzit R,
    8. Balayn D,
    9. Gobin P,
    10. Marchand S,
    11. Couet W
    . 2014. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother58:7324–7330. doi:10.1128/AAC.03508-14.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Yapa WS,
    2. Li J,
    3. Patel K,
    4. Wilson JW,
    5. Dooley MJ,
    6. George J,
    7. Clark D,
    8. Poole S,
    9. Williams E,
    10. Porter CJ,
    11. Nation RL,
    12. McIntosh MP
    . 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother58:2570–2579. doi:10.1128/AAC.01705-13.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Koomanachai P,
    2. Landersdorfer CB,
    3. Chen G,
    4. Lee HJ,
    5. Jitmuang A,
    6. Wasuwattakul S,
    7. Sritippayawan S,
    8. Li J,
    9. Nation RL,
    10. Thamlikitkul V
    . 2014. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother58:440–446. doi:10.1128/AAC.01741-13.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Jitmuang A,
    2. Nation RL,
    3. Koomanachai P,
    4. Chen G,
    5. Lee HJ,
    6. Wasuwattakul S,
    7. Sritippayawan S,
    8. Li J,
    9. Thamlikitkul V,
    10. Landersdorfer CB
    . 2015. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother70:1804–1811. doi:10.1093/jac/dkv031.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ratjen F,
    2. Rietschel E,
    3. Kasel D,
    4. Schwiertz R,
    5. Starke K,
    6. Beier H,
    7. van Koningsbruggen S,
    8. Grasemann H
    . 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother57:306–311. doi:10.1093/jac/dki461.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Sorlí L,
    2. Luque S,
    3. Grau S,
    4. Berenguer N,
    5. Segura C,
    6. Montero MM,
    7. Alvarez-Lerma F,
    8. Knobel H,
    9. Benito N,
    10. Horcajada JP
    . 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis13:380. doi:10.1186/1471-2334-13-380.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Garonzik SM,
    2. Li J,
    3. Thamlikitkul V,
    4. Paterson DL,
    5. Shoham S,
    6. Jacob J,
    7. Silveira FP,
    8. Forrest A,
    9. Nation RL
    . 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother55:3284–3294. doi:10.1128/AAC.01733-10.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Li J,
    2. Coulthard K,
    3. Milne R,
    4. Nation RL,
    5. Conway S,
    6. Peckham D,
    7. Etherington C,
    8. Turnidge J
    . 2003. J Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother52:987–992. doi:10.1093/jac/dkg468.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Luque S,
    2. Grau S,
    3. Valle M,
    4. Sorlí L,
    5. Horcajada JP,
    6. Segura C,
    7. Alvarez-Lerma F
    . 2013. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents42:178–181. doi:10.1016/j.ijantimicag.2013.04.018.
    OpenUrlCrossRef
  11. 11.↵
    1. Markou N,
    2. Fousteri M,
    3. Markantonis SL,
    4. Boutzouka E,
    5. Tsigou E,
    6. Baltopoulo G
    . 2011. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest139:232–233. doi:10.1378/chest.10-1860.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Plachouras D,
    2. Karvanen M,
    3. Friberg LE,
    4. Papadomichelakis E,
    5. Antoniadou A,
    6. Tsangaris I,
    7. Karaiskos I,
    8. Poulakou G,
    9. Kontopidou F,
    10. Armaganidis A,
    11. Cars O,
    12. Giamarellou H
    . 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother53:3430–3436. doi:10.1128/AAC.01361-08.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Boisson M,
    2. Jacobs M,
    3. Grégoire N,
    4. Gobin P,
    5. Marchand S,
    6. Couet W,
    7. Mimoz O
    . 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother58:7331–7339. doi:10.1128/AAC.03510-14.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Couet W,
    2. Grégoire N,
    3. Gobin P,
    4. Saulnier PJ,
    5. Frasca D,
    6. Marchand S,
    7. Mimoz O
    . 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther89:875–879. doi:10.1038/clpt.2011.48.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Gobin P,
    2. Lemaître F,
    3. Marchand S,
    4. Couet W,
    5. Olivier JC
    . 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother54:1941–1948. doi:10.1128/AAC.01367-09.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Froman J,
    2. Gross L,
    3. Curatola S
    . 1970. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol103:210–214.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Bellomo R,
    2. Ronco C,
    3. Kellum JA,
    4. Mehta RL,
    5. Palevsky P
    ,ADQI Workgroup. 2004. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care8:R204–R212. doi:10.1186/cc2872.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Li J,
    2. Milne RW,
    3. Nation RL,
    4. Turnidge JD,
    5. Smeaton TC,
    6. Coulthard K
    . 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother53:837–840. doi:10.1093/jac/dkh167.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Nation RL,
    2. Li J
    . 2009. Colistin in the 21st century. Curr Opin Infect Dis22:535–543. doi:10.1097/QCO.0b013e328332e672.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Li J,
    2. Milne RW,
    3. Nation RL,
    4. Turnidge JD,
    5. Coulthard K,
    6. Johnson DW
    . 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl761:167–175. doi:10.1016/S0378-4347(01)00326-7.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Li J,
    2. Milne RW,
    3. Nation RL,
    4. Turnidge JD,
    5. Coulthard K,
    6. Valentine J
    . 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother46:3304–3307. doi:10.1128/AAC.46.10.3304-3307.2002.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections
Sonia Luque, Carol Escaño, Luisa Sorli, Jian Li, Nuria Campillo, Juan Pablo Horcajada, Esther Salas, Santiago Grau
Antimicrobial Agents and Chemotherapy Jul 2017, 61 (8) e02595-16; DOI: 10.1128/AAC.02595-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections
Sonia Luque, Carol Escaño, Luisa Sorli, Jian Li, Nuria Campillo, Juan Pablo Horcajada, Esther Salas, Santiago Grau
Antimicrobial Agents and Chemotherapy Jul 2017, 61 (8) e02595-16; DOI: 10.1128/AAC.02595-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acinetobacter Infections
Anti-Bacterial Agents
colistin
Pseudomonas Infections
urinary tract infections
colistin
pharmacokinetics
urinary tract infections
Gram-negative bacteria

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596